407 related articles for article (PubMed ID: 26917112)
1. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.
Aberg JA; Tebas P; Overton ET; Gupta SK; Sax PE; Landay A; Falcon R; Ryan R; De La Rosa G
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1184-95. PubMed ID: 22352336
[TBL] [Abstract][Full Text] [Related]
3. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
[TBL] [Abstract][Full Text] [Related]
4. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
Huhn GD; Sigman A; Livak B
Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
[TBL] [Abstract][Full Text] [Related]
5. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
6. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
[TBL] [Abstract][Full Text] [Related]
7. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
[TBL] [Abstract][Full Text] [Related]
8. 96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day
Di Cristo V; Adorni F; Maserati R; Annovazzi Lodi M; Bruno G; Maggi P; Volpe A; Vitiello P; Abeli C; Bonora S; Ferrara M; Cossu MV; Oreni ML; Colella E; Rusconi S
HIV Res Clin Pract; 2020 Feb; 21(1):34-43. PubMed ID: 32129161
[TBL] [Abstract][Full Text] [Related]
9. Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
J Med Econ; 2016; 19(4):386-96. PubMed ID: 26640980
[TBL] [Abstract][Full Text] [Related]
10. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.
Arathoon E; Schneider S; Baraldi E; Lim PL; Opravil M; Van De Casteele T; Lavreys L
Int J STD AIDS; 2013 Jan; 24(1):12-7. PubMed ID: 23440570
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
[TBL] [Abstract][Full Text] [Related]
12. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.
Dentone C; Di Biagio A; Cozzi Lepri A; Fenoglio D; Filaci G; Lichtner M; Carrara S; Giacometti A; Sighinolfi L; Marchetti G; Antinori A; D'arminio Monforte A;
HIV Clin Trials; 2018 Aug; 19(4):158-162. PubMed ID: 30422095
[TBL] [Abstract][Full Text] [Related]
14. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
Nishijima T; Hamada Y; Watanabe K; Komatsu H; Kinai E; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
PLoS One; 2013; 8(10):e77268. PubMed ID: 24130871
[TBL] [Abstract][Full Text] [Related]
15. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
[TBL] [Abstract][Full Text] [Related]
16. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
[TBL] [Abstract][Full Text] [Related]
17. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; de Oliveira CF; Brennan C;
Lancet HIV; 2015 Apr; 2(4):e127-36. PubMed ID: 26424673
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Dierynck I; De Meyer S; Lathouwers E; Vanden Abeele C; Van De Casteele T; Spinosa-Guzman S; de Béthune MP; Picchio G
Antivir Ther; 2010; 15(8):1161-9. PubMed ID: 21149923
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
[TBL] [Abstract][Full Text] [Related]
20. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
Cahn P; Fourie J; Grinsztejn B; Hodder S; Molina JM; Ruxrungtham K; Workman C; Van De Casteele T; De Doncker P; Lathouwers E; Tomaka F
AIDS; 2011 Apr; 25(7):929-39. PubMed ID: 21346512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]